On Nov. 9, 2020, the NIH reported that a pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form of the HIV drug cabotegravir injected once every eight weeks was safe and more effective than a daily oral PrEP regimen at preventing HIV acquisition among a group of cisgender women.

This finding, from a planned interim analysis of study data, marked the first time a large-scale clinical trial has shown a long-acting injectable form of HIV prevention to be highly effective for cisgender women.